# Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

> **NCT01908192** · PHASE2,PHASE3 · TERMINATED · sponsor: **SyneuRx International (Taiwan) Corp** · enrollment: 60 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** NaBen®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01908192
- **Lead sponsor:** SyneuRx International (Taiwan) Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908192, "Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01908192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*